Introduction: Antipsychotic-induced weight-gain (AIWG) is a very important, yet often
neglected side-effect in the treatment with first and second generation antipsychotics. AIWG …

Second generation antipsychotics (SGAs) are effective options in the treatment of
schizophrenia and mood disorders, each with characteristic efficacy and safety features. In …

The British Association for Psychopharmacology guidelines specify the scope and targets of
treatment for bipolar disorder. The third version is based explicitly on the available evidence …

Objective: The authors evaluated the efficacy, safety, and tolerability of cariprazine, an
atypical antipsychotic candidate, in adult patients with acute bipolar I depression. Method …

This phase III study evaluated the efficacy and safety of cariprazine, a dopamine D 3 and D 2
receptor partial agonist with preferential binding to D 3 receptors, in patients with acute …

Objective: Cariprazine, a dopamine D3/D2 and 5-HT1A receptor partial agonist, was found
to be effective in treating bipolar I depression in a previous phase 2 study. This phase 3 …

Objectives: Although clinically highly relevant, the recognition and treatment of bipolar mixed
states has played only an underpart in recent guidelines. This WFSBP guideline has been …

Background: Brexpiprazole and cariprazine are the latest US Food and Drug Administration
approved atypical antipsychotics available in the United States. Both function as partial …

Background: The current paper includes a systematic search of the literature, a detailed
presentation of the results, and a grading of treatment options in terms of efficacy and …

Dopamine (DA), as one of the major neurotransmitters in the central nervous system (CNS)
and periphery, exerts its actions through five types of receptors which belong to two major …